In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4279-4288

  Hindler, Janet A ^a   Wong Beringer, Annie ^b   Charlton, Carmen L ^a,c   Miller, Shelley A ^a   Kelesidis, Theodoros ^a   Carvalho, Marissa ^a   Sakoulas, George ^d   Nonejuie, Poochit ^e   Pogliano, Joseph ^e   Nizet, Victor ^d   Humphries, Romney ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFAZOLIN; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL DNA; BETA LACTAM; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; DRUG COMBINATION;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATE; DAPTOMYCIN NONSUSCEPTIBLE ENTEROCOCCUS; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; EVALUATION STUDY; HUMAN; IN VITRO STUDY; LIAFSR GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YYCFGHIJ GENE; DNA MUTATIONAL ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; ENTEROCOCCUS FAECIUM; GENETICS; GRAM POSITIVE INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY;

AMPICILLIN; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-LACTAMS; DAPTOMYCIN; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; RIFAMPIN; VANCOMYCIN RESISTANCE;

EID: 84931282069     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05077-14     Document Type: Article

References (46)

1. th informational supplement, vol M100 S24. CLSI, Wayne, PA.
2. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). Int J Antimicrob Agents 43:465-469. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.018.
3. Kelesidis T, Chow AL, Humphries R, Uslan DZ, Pegues D. 2012. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections. Antimicrob Agents Chemother 56:2150-2152. http://dx.doi.org/10.1128/AAC.05918-11.
4. Kelesidis T, Humphries R, Uslan DZ, Pegues D. 2012. De novo daptomycin-non-susceptible enterococcal infections. Emerg Infect Dis 18:674-676. http://dx.doi.org/10.3201/eid1804.110932.
5. Kelesidis T, Humphries R, Chow AL, Tsiodras S, Uslan DZ. 2013. Emergence of daptomycin-non-susceptible enterococci urinary tract isolates. J Med Microbiol 62:1103-1105. http://dx.doi.org/10.1099/jmm.0.056630-0.
6. Lewis JS, II, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49:1664-1665. http://dx.doi.org/10.1128/AAC.49.4.1664-1665.2005.
7. Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41:565-566. http://dx.doi.org/10.1086/432121.
8. Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wanger A, Murray BE. 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 45:1343-1346. http://dx.doi.org/10.1086/522656.
9. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. 2004. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 24:59-66. http://dx.doi.org/10.1016/j.ijantimicag.2003.12.014.
10. Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA. 2012. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56:4354-4359. http://dx.doi.org/10.1128/AAC.00509-12.
11. Munita JM, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Arias CA. 2013. A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 57:2831-2833. http://dx.doi.org/10.1128/AAC.00021-13.
12. Streit JM, Jones RN, Sader HS. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 53:669-674. http://dx.doi.org/10.1093/jac/dkh143.
13. Diaz L, Tran TT, Munita JM, Miller WR, Rincon S, Carvajal LP, Wollam A, Reyes J, Panesso D, Rojas NL, Shamoo Y, Murray BE, Weinstock GM, Arias CA. 2014. Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrob Agents Chemother 58:4527-4534. http://dx.doi.org/10.1128/AAC.02686-14.
14. Miller C, Kong J, Tran TT, Arias CA, Saxer G, Shamoo Y. 2013. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob Agents Chemother 57:5373-5383. http://dx.doi.org/10.1128/AAC.01473-13.
15. Munita JM, Mishra NN, Alvarez D, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Adachi JA, Bayer AS, Arias CA. 8 August 2014, posting date. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis http://dx.doi.org/10.1093/cid/ciu642.
16. Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ. 23 June 2014. Defining daptomycin resistance prevention exposures in vancomycin resistant Enterococcus (VRE) faecium and E. faecalis. Antimicrob Agents Chemother http://dx.doi.org/10.1128/AAC.00098-14.
17. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:838-844. http://dx.doi.org/10.1128/AAC.05551-11.
18. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. 2014. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 58:1494-1500. http://dx.doi.org/10.1128/AAC.02274-13.
19. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. 2013. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 57:4042-4045. http://dx.doi.org/10.1128/AAC.02481-12.
20. rd ed, vol 2. ASM, Washington, DC.
21. th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
22. Foulds G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 8(Suppl 5):S503-S511.
23. Sagent Pharmaceuticals. 2012. Cefazolin for injection, USP (package insert). Sagent Pharmaceuticals, Schaumburg, IL.
24. Goonetilleke AK, Dev D, Aziz I, Hughes C, Smith MJ, Basran GS. 1996. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J Antimicrob Chemother 38:969-976. http://dx.doi.org/10.1093/jac/38.6.969.
25. Forest Laboratories Inc. 2010. Teflaro (ceftaroline fosamil) injection for intravenous (IV) use. Forest Pharmaceuticals, Inc., St. Louis, MO.
26. Frasca D, Marchand S, Petitpas F, Dahyot-Fizelier C, Couet W, Mimoz O. 2010. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob Agents Chemother 54:924-926. http://dx.doi.org/10.1128/AAC.00836-09.
27. Baxter Corporation. 2012. Gentamicin sulfate in 0.9% sodium chloride injection. Baxter Corporation, Mississauga, ON, Canada.
28. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. http://dx.doi.org/10.1378/chest.115.1.12.
29. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP. 2005. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49:1629-1632. http://dx.doi.org/10.1128/AAC.49.4.1629-1632.2005.
30. American Society for Microbiology. 2014. In vitro susceptibility tests. In Instructions to authors (Antimicrobial Agents and Chemotherapy). American Society for Microbiology, Washington, DC.
31. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 52:228-234. http://dx.doi.org/10.1093/cid/ciq113.
32. Gould IM, Miro JM, Rybak MJ. 2013. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42:202-210. http://dx.doi.org/10.1016/j.ijantimicag.2013.05.005.
33. Cilli F, Aydemir S, Tunger A. 2006. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 18:27-32. http://dx.doi.org/10.1179/joc.2006.18.1.27.
34. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. 1990. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 26:619-626. http://dx.doi.org/10.1093/jac/26.5.619.
35. Duez JM, Péchinot A, Siébor E, Cordin X, Kazmierczak A. 1989. Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus. Pathol Biol (Paris) 37:263-268. (In French.)
36. Rand KH, Houck H. 2004. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 53:530-532. http://dx.doi.org/10.1093/jac/dkh104.
37. Mobarakai N, Quale JM, Landman D. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother 38:385-387. http://dx.doi.org/10.1128/AAC.38.2.385.
38. nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA, p 53.
39. Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. 2012. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 56:6064. http://dx.doi.org/10.1128/AAC.01760-12.
40. Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Cremieux AC, Bayer AS. 2013. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. http://dx.doi.org/10.1371/journal.pone.0071151.
41. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. 1991. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 35:92-98. http://dx.doi.org/10.1128/AAC.35.1.92.
42. Munita JM, Murray BE, Arias CA. 2 September 2014, posting date. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents http://dx.doi.org/10.1016/j.ijantimicag.2014.08.002.
43. Sahm DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, Solliday J, Clarke B. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 33:1588-1591. http://dx.doi.org/10.1128/AAC.33.9.1588.
44. Schutt AC, Bohm NM. 2009. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Annals Pharmacother 43:2108-2112. http://dx.doi.org/10.1345/aph.1M324.
45. Polidori M, Nuccorini A, Tascini C, Gemignani G, Iapoce R, Leonildi A, Tagliaferri E, Menichetti F. 2011. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother 23:240-241. http://dx.doi.org/10.1179/joc.2011.23.4.240.
46. Jenkins I. 2007. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2:343-344. http://dx.doi.org/10.1002/jhm.236.